Pharmacological inhibition of poly(adp-ribose) polymerase (parp) activity in parp-1 silenced tumour cells increases chemosensitivity to temozolomide and to a n3-adenine selective methylating agent

Current Cancer Drug Targets

Volumn 10, Issue 4, 2010, Pages 368-383

  Tentori, L ^a   Muzi, A ^a   Dorio, A S ^a   Scarsella, M ^b   Leonetti, C ^b   Shah, G M ^c   Xu, W ^d   Camaioni, E ^e   Gold, B ^f   Pellicciari, R ^e   Dantzer, F ^g   Zhang, J ^h   Graziani, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c LAVAL UNIVERSITY   (Canada)

^d XUZHOU MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g UNIVERSITÉ DE STRASBOURG   (France)

^h Profectus BioSciences Inc   (United States)

Author keywords

Me lex; Melanoma; Poly(adp ribose) polymerase; Temozolomide

Indexed keywords

1METHYL 4 [1 METHYL 4 (3 METHOXYSULFONYLPROPANAMIDO)PYRROLE 2 CARBOXAMIDO] PYRROLE 2 CARBOXAMIDO)PROPANE; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; DACARBAZINE; DRUG SYNERGISM; ENZYME INHIBITORS; FLOW CYTOMETRY; G2 PHASE; HELA CELLS; HUMANS; MELANOMA, EXPERIMENTAL; METHYLATION; MICE; NETROPSIN; POLY(ADP-RIBOSE) POLYMERASES;

EID: 77953668745     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791208571     Document Type: Article

References (35)

1. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell. Biol. 2006, 7, 517-528.
2. Tentori, L.; Graziani, G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res. 2005, 52, 25-33.
3. Yélamos, J.; Schreiber, V.; Dantzer, F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol. Med. 2008, 14, 169-178.
4. Schreiber, V.; Amé, J. C.; Dollé, P.; Schultz, I.; Rinaldi, B.; Frau-lob, V.; Ménissier-de Murcia, J.; de Murcia, G. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. 2002, 277, 23028-23036.
5. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
6. Tentori, L.; Graziani, G. Recent approaches to improve the antitu-mour efficacy of temozolomide. Curr. Med. Chem. 2009, 16, 245257.
7. Newlands, E. S.; Stevens, M. F.; Wedge, S. R.; Wheelhouse, R. T.; Brock, C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 1997, 23, 35-61.
8. Dantzer, F.; Schreiber, V.; Niedergang, C.; Trucco, C.; Flatter, E.; De La Rubia, G.; Oliver, J.; Rolli, V.; Menissier-de Murcia, J.; de Murcia, G. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 1999, 81, 69-75.
9. Gerson, S. L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004, 4, 296-307.
10. D'Atri, S.; Tentori, L.; Lacal, P. M.; Graziani, G.; Pagani, E.; Benincasa, E.; Zambruno, G.; Bonmassar, E.; Jiricny J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol. 1998, 54, 334-341.
11. Ratnam, K.; Low, J. A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 2007, 13, 1383-1388.
12. Encell, L.; Shuker, D. E.; Foiles, P. G.; Gold B. The in vitro methy-lation of DNA by a minor groove binding methyl sulfonate ester. Chem. Res. Toxicol. 1996, 9, 563-567.
13. Kelly, J. D.; Inga, A.; Chen, F. X.; Dande, P.; Shah, D.; Monti, P.; Aprile, A.; Burns, P. A.; Scott, G.; Abbondandolo, A.; Gold, B.; Fronza, G. Relationship between DNA methylation and mutational patterns induced by a sequence selective minor groove methylating agent. J. Biol. Chem. 1999, 274, 18327-18334.
14. Tentori, L.; Portarena, I.; Vernole, P.; Gold, B.; Graziani, G. Apop-totic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polym-erase inhibitors in normal peripheral blood lymphocytes. Cancer Chemother. Pharmacol. 2002, 49, 217-224.
15. Tentori. L.; Vernole, P.; Lacal, P. M.; Madaio, R.; Portarena, I.; Levati, L.; Balduzzi, A.; Turriziani, M.; Dande, P.; Gold, B.; Bon-massar, E.; Graziani, G. Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells. Leukemia 2000, 14, 1451-1459.
16. Tentori, L.; Balduzzi, A.; Portarena, I.; Levati, L.; Vernole, P.; Gold, B.; Bonmassar, E.; Graziani, G. Poly (ADP-ribose) polym-erase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death Differ. 2001, 8, 817-828.
17. Tentori, L.; Forini, O.; Fossile, E.; Muzi, A.; Vergati, M.; Por-tarena, I.; Amici, C.; Gold, B.; Graziani, G. N3-methyladenine induces early poly (ADP-ribosylation), reduction of NF-kB DNA binding ability and nuclear up-regulation of telomerase activity. Mol. Pharmacol. 2005, 67, 572-581.
18. Tentori, L.; Muzi, A.; Dorio, A. S.; Bultrini, S.; Mazzon, E.; Lacal, P. M.; Shah, G. M.; Zhang, J.; Navarra, P.; Nocentini, G.; Cuz-zocrea, S.; Graziani, G. Stable depletion of poly (ADP-ribose) po-lymerase-1 reduces in vivo melanoma growth and increases che-mosensitivity. Eur. J. Cancer 2008, 44, 1302-1314.
19. Bai, P.; Houten, S. M.; Huber, A.; Schreiber, V.; Watanabe, M.; Kiss, B.; de Murcia, G.; Auwerx, J.; Menissier-de Murcia, J. Poly(ADP-ribose) polymerase-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid X receptor/peroxisome proliferator-activated receptor-gamma heterodimer. J. Biol. Chem. 2007, 282, 37738-37746.
20. Shah, R. G.; Ghodgaonkar, M. M.; Affar el, B.; Shah, G. M. DNA vector-based RNAi approach for stable depletion of poly(ADP-ribose) polymerase-1. Biochem. Biophys. Res. Commun. 2005, 331, 167-174.
21. Zhang, Y.; Chen, F. -X.; Mehta, P.; Gold, B. The design of groove and sequence selective alkylation of DNA by sulfonate esters tethered to lexitropsin. Biochemistry 1993, 32, 7954-7965.
22. Tentori, L.; Leonetti, C.; Scarsella, M.; D'Amati, G.; Vergati, M.; Portarena, I.; Xu, W.; Kalish, V.; Zupi, G.; Zhang, J.; Graziani, G. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumour activity of temo-zolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 2003, 9, 5370-5379.
23. Pellicciari, R.; Camaioni, E.; Costantino, G.; Formentini, L.; Sab-batini, P.; Venturoni, F.; Eren, G.; Bellocchi, D.; Chiarugi, A.; Moroni, F. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. Chem. Med. Chem. 2008, 3, 914-923.
24. Preuss, I.; Thust, R.; Kaina, B. Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int. J. Cancer 1996, 65, 506-512.
25. Tentori, L.; Leonetti, C.; Scarsella, M.; Vergati, M.; Xu, W.; Calvin, D.; Morgan, L.; Tang, Z.; Woznizk, K.; Alemu, C.; Hoover, R.; Lapidus, R.; Zhang, J.; Graziani, G. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumours. Int. J. Oncol. 2005, 26, 415-422.
26. Horton, T. M.; Jenkins, G.; Pati, D.; Zhang, L.; Dolan, M. E.; Ribes-Zamora, A.; Bertuch, A. A.; Blaney, S. M.; Delaney, S. L.; Hegde, M.; Berg, S. L. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol. Cancer Ther. 2009, 8, 2232-2242.
27. Drew, Y; Plummer, R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat. 2009, 12, 153-156.
28. Williamson, C. T.; Muzik, H; Turhan, A. G.; Zamo, A.; O'Connor, M. J.; Bebb, D. G.; Lees-Miller, S. P. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol. Cancer Ther. 2010, 9, 347-357.
29. Tentori, L.; Lacal, P. M.; Muzi, A.; Dorio, A. S.; Leonetti, C.; Scarsella, M.; Ruffini, F.; Xu, W.; Min, W.; Stoppacciaro, A.; Co-larossi, C.; Wang, Z. Q.; Zhang, J.; Graziani, G. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer 2007, 43, 2124-2133.
30. Horton, J. K.; Stefanick, D. F.; Naron, J. M.; Kedar, P. S.; Wilson, S. H. Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure. J. Biol. Chem. 2005, 280, 15773-15785.
31. Peng, C. Y.; Graves, P. R.; Thoma, R. S.; Wu, Z.; Shaw, A. S.; Piwnica-Worms, H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277, 1501-1505.
32. Graves, P. R.; Yu, L.; Schwarz, J. K.; Gales, J.; Sausville, E. A.; O'Connor, P. M.; Piwnica-Worms, H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 2000, 275, 5600-5605.
33. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24, 1770-1783.
34. Stark, G. R.; Taylor, W. R. Control of the G2/M transition. Mol. Biotechnol. 2006, 32, 227-248.
35. Taylor, W. R.; Stark, G. R. Regulation of the G2/M transition by p53. Oncogene 2001, 20, 1803-1815.